| Code | CSB-RA004847MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US11859000B2, targeting C-C chemokine receptor type 8 (CCR8). CCR8 is a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs), particularly tumor-infiltrating Tregs, and certain T helper 2 (Th2) cells. This receptor mediates chemotaxis in response to its ligands CCL1 and CCL18, playing a critical role in immune cell trafficking and localization within tissues. CCR8 has emerged as a significant target in immuno-oncology research due to its preferential expression on intratumoral Tregs, which suppress anti-tumor immune responses and contribute to immune evasion in various cancers including colorectal, breast, and lung carcinomas.
The reference antibody represents a therapeutic candidate designed to selectively deplete CCR8-positive Tregs within the tumor microenvironment while preserving systemic immune homeostasis. This biosimilar provides researchers with a valuable tool for investigating CCR8-mediated immune regulation, Treg biology, and potential immunotherapeutic strategies in cancer models and immunological studies.
There are currently no reviews for this product.